Vyome Holdings, Inc. Common Stock
$2.00
$0.04 (+1.79%)
$1.97Day Range$2.01
Key Statistics
Market Cap
$13.76M
Shares Outstanding
7.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Aug 15, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$1.97
Day High
$2.01
Day Low
$1.97
Volume
5.5K
VWAP
$2.00
Prev Close
$1.96
Transactions
--
Acc. Volume
--
About Vyome Holdings, Inc. Common Stock
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
PHARMACEUTICAL PREPARATIONSSIC 283418 employees1001 CALLE AMANECER, SAN CLEMENTE, CA, 92673949-429-6680IPO Aug 15, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001427570
- Composite FIGI
- BBG0036S6JY0
- Share Class FIGI
- BBG0036S6JZ9
- Ticker Root
- HIND
- SIC Code
- 2834
About Vyome Holdings, Inc. Common Stock (HIND) Stock
Vyome Holdings, Inc. Common Stock (HIND) closed the 2026-09-18 session at $2.00, up 1.79% versus the previous close (+0.04). The stock opened at $1.97 and traded between $1.97 and $2.01 during that session. Session trading volume was 5K shares. The volume-weighted average price (VWAP) is $2.00.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Vyome Holdings, Inc. Common Stock has a market capitalization of $13.8 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. HIND is listed on the XNAS exchange. The company employs approximately 18 people. Vyome Holdings, Inc. Common Stock is headquartered in SAN CLEMENTE, CA. The recorded listing date is 2025-08-15.
On this page you can find market HIND stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.